Union Therapeutics starts phase II trial of nasal spray for Covid-19 patients

The Danish biotech company Union Therapeutics has enrolled the first patient in its phase II trial of drug candidate niclosamide as a treatment for Covid-19 patients, it reports in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Danish Covid-19 treatment approved for human trials
For subscribers
EMA to investigate Covid-19 treatment
For subscribers